IDP-121 Plus Chemotherapy for Small Cell Lung Cancer That Has Come Back
Tests IDP-121 with chemotherapy in adults with relapsed small cell lung cancer.
Key facts
- Who runs it
- Idp Discovery Pharma S.L.
- Where
- Badalona, Barcelona, Las Palmas De Gran Canaria, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, and Valencia, SpainSee the 10 sites
- Trial code
- Registry title
- Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 60 people, planned
- Started
- 9 Jul 2026
- Expected to end
- 31 May 2029
- Type of study
- Interventional
- Record updated
- 4 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced small cell lung cancer that came back after first treatment. They get IDP-121 together with chemotherapy.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Advanced or extensive stage small cell lung cancer (SCLC) that came back after first-line treatment. Progression Free Interval of 3 months or more goes to the platinum-based chemotherapy plus IDP-121 arm. Less than 3 months goes to the topotecan plus IDP-121 arm.
- Earlier treatment
- First-line treatment for SCLC. Must not have had other anti-tumour therapy within 14 days before Day 1 of Cycle 1. No allogeneic transplant in the last 3 months.
Main reasons for not taking part
- Active brain metastases or carcinomatous meningitis
- Pregnant or breastfeeding women
- Another cancer in the last five years (some skin cancers and carcinoma in situ are allowed)
- Heart failure, angina or heart attack within 12 months
- Clinically significant or active infection
Where in Spain
- Hospital Germans Trias i PujolBadalona, SpainTaking people
- Hospital del MarBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- El Hospital Universitario De Gran Canaria Dr. NegrinLas Palmas De Gran Canaria, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
- Hospital Universitario de NavarraPamplona, SpainTaking people
- Hospital Universitario Nuestra Señora de CandelariaSanta Cruz de Tenerife, SpainTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
About the trial
What the trial wants to find out
Dose-Escalation Phase (Phase 1) Primary objective: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 combined with chemotherapy (topotecan day 1 to 5 every 3 weeks; carboplatin day 1 plus etoposide days 1, 2 and 3 every 3 weeks) in patients with SCLC. Expansion Phase (Phase 2): Primary objective To evaluate the overall response rate (ORR) and disease control rate (DCR) of IDP-121 combined with chemotherapy in patients with SCLC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)
- Plain-language title
- IDP-121 Plus Chemotherapy for Small Cell Lung Cancer That Has Come BackGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 4 May 2026